How can proteomics elucidate the complexity of multiple sclerosis?
Multiple sclerosis affects more than 2.5 million people worldwide. Although multiple sclerosis was described almost 150 years ago, there are many knowledge gaps regarding its etiology, diagnosis, prognosis, and pathogenesis. Multiple sclerosis is an inflammatory, demyelinating, neurodegenerative disease of the CNS. During the last several decades, experimental models of multiple sclerosis have contributed to our understanding of the inflammatory disease mechanisms and have aided drug testing and development. However, little is known about the neurodegenerative mechanisms that operate during the evolution of the disease. Currently, all therapeutic approaches are primarily based on the inflammatory aspect of the disease. During the last decade, proteomics has emerged as a promising tool for revealing molecular pathways as well as identifying and quantifying differentially expressed proteins. Therefore, proteomics may be used for the discovery of biomarkers, potential drug targets, and new regulatory mechanisms. To date, a considerable number of proteomics studies have been conducted on samples from experimental models and patients with multiple sclerosis. These data form a solid base for further careful analysis and validation.
['Farias|Alessandro S|AS|', 'Santos|Leonilda M B|LM|']
D000818:Animals D004681:Encephalomyelitis, Autoimmune, Experimental D006801:Humans D009103:Multiple Sclerosis D019636:Neurodegenerative Diseases D040901:Proteomics
Proteomics Multiple sclerosis Experimental autoimmune encephalomyelitis Inflammation Neurodegeneration